TY - JOUR
T1 - S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder
T2 - An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine
AU - Alpert, Jonathan E.
AU - Papakostas, George
AU - Mischoulon, David
AU - Worthington, John J.
AU - Petersen, Timothy
AU - Mahal, Yasmin
AU - Burns, Alana
AU - Bottiglieri, Teodoro
AU - Nierenberg, Andrew A.
AU - Fava, Maurizio
PY - 2004/12
Y1 - 2004/12
N2 - Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.
AB - Background: The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine. Method: Thirty antidepressant-treated adult outpatients with persisting major depressive disorder received 800 to 1600 mg of S-adenosyl-L-methionine tosylate over a 6-week trial. Results: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. Conclusion: Augmentation of selective serotonin reuptake inhibitors or venlafaxine with S-adenosyl-L-methionine warrants a placebo-controlled trial in resistant depression.
UR - http://www.scopus.com/inward/record.url?scp=8744287602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8744287602&partnerID=8YFLogxK
U2 - 10.1097/01.jcp.0000145339.45794.cd
DO - 10.1097/01.jcp.0000145339.45794.cd
M3 - Article
C2 - 15538131
AN - SCOPUS:8744287602
SN - 0271-0749
VL - 24
SP - 661
EP - 664
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 6
ER -